Latest News

This lesser-known dividend stock offers a yield above 4% and a potentially powerful earnings growth catalyst that could help it outperform Coca-Cola and PepsiCo over the next decade.

Factory utilization in the mid-80% range and a path to 60% gross margins suggest NXP is positioned to convert structural growth into shareholder returns.

Unified branding and discounted oil-change campaigns are lifting repair traffic, helping offset pressure from vehicle affordability headwinds.

Satellite scale meets drone agility, but one company's revenue jumped 508% while the other's forward multiple tells a very different valuation story.

AT&T and Verizon both trade at similar valuations, but their paths diverge sharply in other areas.

Netflix's core competitive advantage should drive great long-term results.

Alibaba and Uber both lead their markets, but one trades at a far lower earnings multiple while the other is priced for sustained high growth.

Buffett’s wisdom is timeless.

Credo's revenue surged past 160% in the latest twelve months, but Marvell's $9.5 billion scale and heavier debt load tell a very different story for investors.

It could still get better from here.

Hotter-than-expected inflation in October means the Fed may raise its target rate by a half percentage point next month.

Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.

Michael Saylor just floated up to $30 billion in new financing for Strategy. Here's what that number does and doesn't mean.

AGNC’s book value plunged 17% in one quarter, yet its 17.5%-yielding dividend didn’t budge. Here’s why the payout looks safe for now.

Arm and ASML sit at opposite ends of the chip supply chain, but a sharp gap in their valuations may tip the scales for cautious buyers.

Synopsys earns nearly $1.3 billion in net income on $7.1 billion in revenue, while SentinelOne is still posting a net loss despite 21.9% growth.

Component shortages are holding back shipments, so near-term revenue depends on securing parts rather than on demand alone.

Arista's margins are running hot, but IBM's steady software pivot and far lower valuation make the 2027 choice closer than the price tags suggest.

Only seven past stretches since 1950 lasted this long. Did a tough year normally follow?

Innodata's revenue jumped nearly 47% while Nebius posted a far steeper climb, but their valuations and risk profiles tell very different stories.

D-Wave Quantum grew third-quarter revenue 21%, but its stock trades at a steep multiple. Here is how far it would need to grow to match IonQ's size.

The $1.3 billion liquidity cushion gives the company room to scale production without dilutive financing, but integrating facilities across eight states will test that discipline.

Realty Income's 5.4% yield isn't paid quarterly, which can change everything if you are trying to live off your dividend income.

Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors.